| pubmed-article:11745288 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11745288 | lifeskim:mentions | umls-concept:C1168401 | lld:lifeskim |
| pubmed-article:11745288 | lifeskim:mentions | umls-concept:C0079083 | lld:lifeskim |
| pubmed-article:11745288 | lifeskim:mentions | umls-concept:C0144576 | lld:lifeskim |
| pubmed-article:11745288 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:11745288 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:11745288 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:11745288 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:11745288 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:11745288 | pubmed:dateCreated | 2001-12-17 | lld:pubmed |
| pubmed-article:11745288 | pubmed:abstractText | Two-thirds of patients with squamous cell carcinomas of the head and neck (SCCHN) at diagnosis have advanced disease with projected 5-year survival rates of 30%. In those patients with distant metastatic or previously treated recurrent disease, response rate to the standard regimen of cisplatin and 5-fluorouracil is approximately 30%. The authors investigated the use of paclitaxel and carboplatin in a limited Phase II study in recurrent or metastatic SCCHN to evaluate tumor response, time to progression, survival, and toxicities of this regimen. | lld:pubmed |
| pubmed-article:11745288 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11745288 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11745288 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:11745288 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11745288 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11745288 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11745288 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11745288 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:11745288 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:11745288 | pubmed:author | pubmed-author:EmamiBB | lld:pubmed |
| pubmed-article:11745288 | pubmed:author | pubmed-author:MatzGG | lld:pubmed |
| pubmed-article:11745288 | pubmed:author | pubmed-author:CollinsSS | lld:pubmed |
| pubmed-article:11745288 | pubmed:author | pubmed-author:ChoudhuryAA | lld:pubmed |
| pubmed-article:11745288 | pubmed:author | pubmed-author:MelianEE | lld:pubmed |
| pubmed-article:11745288 | pubmed:author | pubmed-author:ClarkJ IJI | lld:pubmed |
| pubmed-article:11745288 | pubmed:author | pubmed-author:PetruzzelliGG | lld:pubmed |
| pubmed-article:11745288 | pubmed:author | pubmed-author:BastianRR | lld:pubmed |
| pubmed-article:11745288 | pubmed:author | pubmed-author:HofmeisterCC | lld:pubmed |
| pubmed-article:11745288 | pubmed:copyrightInfo | Copyright 2001 American Cancer Society. | lld:pubmed |
| pubmed-article:11745288 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11745288 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:11745288 | pubmed:volume | 92 | lld:pubmed |
| pubmed-article:11745288 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11745288 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11745288 | pubmed:pagination | 2334-40 | lld:pubmed |
| pubmed-article:11745288 | pubmed:dateRevised | 2006-4-24 | lld:pubmed |
| pubmed-article:11745288 | pubmed:meshHeading | pubmed-meshheading:11745288... | lld:pubmed |
| pubmed-article:11745288 | pubmed:meshHeading | pubmed-meshheading:11745288... | lld:pubmed |
| pubmed-article:11745288 | pubmed:meshHeading | pubmed-meshheading:11745288... | lld:pubmed |
| pubmed-article:11745288 | pubmed:meshHeading | pubmed-meshheading:11745288... | lld:pubmed |
| pubmed-article:11745288 | pubmed:meshHeading | pubmed-meshheading:11745288... | lld:pubmed |
| pubmed-article:11745288 | pubmed:meshHeading | pubmed-meshheading:11745288... | lld:pubmed |
| pubmed-article:11745288 | pubmed:meshHeading | pubmed-meshheading:11745288... | lld:pubmed |
| pubmed-article:11745288 | pubmed:meshHeading | pubmed-meshheading:11745288... | lld:pubmed |
| pubmed-article:11745288 | pubmed:meshHeading | pubmed-meshheading:11745288... | lld:pubmed |
| pubmed-article:11745288 | pubmed:meshHeading | pubmed-meshheading:11745288... | lld:pubmed |
| pubmed-article:11745288 | pubmed:meshHeading | pubmed-meshheading:11745288... | lld:pubmed |
| pubmed-article:11745288 | pubmed:meshHeading | pubmed-meshheading:11745288... | lld:pubmed |
| pubmed-article:11745288 | pubmed:meshHeading | pubmed-meshheading:11745288... | lld:pubmed |
| pubmed-article:11745288 | pubmed:meshHeading | pubmed-meshheading:11745288... | lld:pubmed |
| pubmed-article:11745288 | pubmed:meshHeading | pubmed-meshheading:11745288... | lld:pubmed |
| pubmed-article:11745288 | pubmed:meshHeading | pubmed-meshheading:11745288... | lld:pubmed |
| pubmed-article:11745288 | pubmed:meshHeading | pubmed-meshheading:11745288... | lld:pubmed |
| pubmed-article:11745288 | pubmed:meshHeading | pubmed-meshheading:11745288... | lld:pubmed |
| pubmed-article:11745288 | pubmed:meshHeading | pubmed-meshheading:11745288... | lld:pubmed |
| pubmed-article:11745288 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11745288 | pubmed:articleTitle | Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma. | lld:pubmed |
| pubmed-article:11745288 | pubmed:affiliation | Department of Medicine, Division of Hematology/Oncology, Loyola University Medical Center/Cardinal Bernardin Cancer Center, 2160 South First Avenue, Maywood, IL 60153, USA. jclark@lumc.edu | lld:pubmed |
| pubmed-article:11745288 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11745288 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11745288 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11745288 | lld:pubmed |
